title: [Screening in open angle glaucoma].
abstract: Primary open angle glaucoma (POAG) represents the second cause of mondial cecity, after retinal diabetes complications, with extremely severe implications in quality of life. Screening testing for glaucoma is justified, because only the diagnosis in very incipient stage will preserve the visual function; any treatment will not assure the reversibility of pre-existent optic nerve lesions. Screening of glaucoma, will take into a consideration the costs, the time of investigation, the adverse effects, and the sensitivity and specificity of tests; the last parameter also will strongly influence the positive predictive value. An ideal screening identifies all subjects that present the disease (sensitivity) and will exclude all healthy subjects (specificity). In this moment, in Dolj district, the diagnosis is based on active diagnosis of new cases of glaucoma on the high risk level population, therefore in a 210000 habitants. 4723 patients with glaucoma are diagnosed, screened and follow-up on medical cabinets and on Center of Glaucoma, which coordinates their activity. To better monitored patients, automatized programs with acquisition and storage for different types of medical imaging facilities had become indispensable to any routine practice.
authors.forename: Carmen
authors.initials: C
authors.lastname: Mocanu
authors.forename: Andrei
authors.initials: A
authors.lastname: Mocanu
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D003598:Cytoskeletal Proteins / Q000235:genetics*; D042241:Early Diagnosis; D019317:Evidence-Based Medicine; D005136:Eye Proteins / Q000235:genetics*; D020869:Gene Expression Profiling; D005902:Glaucoma, Open-Angle / Q000175:diagnosis* / Q000191:economics / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D014943:Global Health; D006023:Glycoproteins / Q000235:genetics*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008403:Mass Screening / Q000191:economics / Q000379:methods / Q000639:trends; D009154:Mutation; D009901:Optic Nerve Diseases / Q000175:diagnosis; D011237:Predictive Value of Tests; D015995:Prevalence; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012383:Romania / Q000453:epidemiology; D012680:Sensitivity and Specificity; D041623:Tomography, Optical Coherence / Q000379:methods; D014130:Trabeculectomy / Q000379:methods; D016896:Treatment Outcome; D058609:Visual Field Tests / Q000379:methods; D000099179:Myocilin
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D003598:Cytoskeletal Proteins; D005136:Eye Proteins; D006023:Glycoproteins; D000099179:Myocilin